MDT perspectives on tracking prognostic and predictive biomarkers for immunotherapy
touchMDT for touchONCOLOGY
Listen to key experts from a multidisciplinary team discuss the tools used to predict response to immunotherapy, and they review emerging biomarkers.
The multidisciplinary team:
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/mdt-immunotherapies-for-metastatic-nsclc-without-driver-mutations/
Create your
podcast in
minutes
It is Free